<div id="readability-page-1"><p>William Blair analyst Matt Phipps has maintained their bullish  stance on <span>CGEM</span> stock, giving a Buy rating on December 2.</p><h3>TipRanks Cyber Monday Sale</h3><ul><li> Claim 60% off TipRanks Premium  for data-backed insights and research tools you need to invest with confidence.  </li><li>  Subscribe to TipRanks' Smart Investor Picks  and see our data in action through our high-performing model portfolio - <u> now also 60% off </u></li></ul> <p>Matt Phipps has given his Buy rating due to a combination of factors including the promising data presented by Cullinan Management for their CLN-049 therapy in treating relapsed/refractory acute myeloid leukemia (AML). The Phase I study results demonstrated complete response rates that align with historical benchmarks for similar therapies, alongside a favorable safety profile that suggests potential for use in combination treatments.<br/>Additionally, the data revealed encouraging signals of durability, with one patient maintaining a complete response for over 36 weeks. The positive market reaction, with Cullinan’s shares rising significantly, reflects investor confidence in the strong efficacy and safety profile of CLN-049. These factors contribute to the optimistic outlook for Cullinan Management’s stock, supporting the Buy rating.</p> <p>In another report released on December 2, BTIG also maintained a Buy rating on the stock with a $38.00 price target.</p> </div>

CGEM

<p>William Blair analyst Matt Phipps maintains a Buy rating on Cullinan Management (CGEM) due to promising CLN-049 therapy results for AML. The Phase I study shows complete response rates and a favorable safety profile, boosting investor confidence and stock price. BTIG also supports a Buy rating with a $38 target.</p>

Optimistic Buy Rating for Cullinan Management Driven by Promising CLN-049 Therapy Results